Business
Wegovy Maker Novo Bets on New Drugs to Combat Lilly’s Dominance
Novo Nordisk NOVO.B -7.65%decrease; down pointing triangle Chief Executive Mike Doustdar, who took over in 2025 promising to find a sustainable growth path, said the company will launch several new blockbusters over the next few years but investors aren’t yet convinced the Danish drugmaker is close to finding its next Ozempic.
Novo’s shares were down roughly 8% on Monday during the company’s investor day in London.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
You must be logged in to post a comment Login